shutterstock_1437879773_edited.jpg
 

AmMax Partnering

AmMax is built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. We plan to continue to build out the anti-inflammatory, anti-fibrotic and anti-neovascular CSF1R technology platform through research collaborations and partnering. We are also interested in partnering to complement our existing portfolio.

AmgenLogo_Blue_spot_WithoutTag_2.tif

LifeMax licensed the worldwide rights to AMG820, now designated AMB-05X, which is in clinical development for tenosynovial giant cell tumor. The same molecule is also being developed for idiopathic pulmonary fibrosis, polycystic kidney diseases and an undisclosed indication.